Abstract 2494
Background
CAR-T cells are a new cancer treatment, where T cells are taken from the patient and modified in a laboratory to target cancer cells. There have been some promising results from early clinical trials, which have led to two products being made available to patients in the NHS. Axicabtagene ciloleucel for relapsed/refractory B-cell lymphoma patients and tisagenlecleucel for relapsed/refractory B-cell lymphoma patients and relapsed/refractory B-ALL patients under the age of 25. There are multiple clinical trials in progress throughout Europe, mostly in the haematology setting, with some in oncology. There are significant toxicities to this treatment modality and this is a complex heavily pre-treated patient population. Education of the wider nursing and multi professional team is therefore crucial. A new Lecturer Practitioner role was established, to focus on CAR-T. This poster explores nurses’ learning needs associated with introducing CAR-T therapy in a specialist cancer hospital in London, UK.
Methods
Data has been collected through evaluation of previous nursing educational initiatives in CAR-T therapy, which aimed to identify further learning needs. Further data collection is in development.
Results
Although this work is on-going, initial findings indicate that nurses require more education and support particularly around managing toxicities and patient expectations. Challenges for educating nurses also include uncertainties around the long-term effects of this treatment modality.
Conclusions
CAR-T therapy is being implemented at multiple centres throughout the UK/Europe and it is evident that there are a multitude of future opportunities for career development for nurses in this area. The role of a Lecturer Practitioner in CAR-T at a specialist cancer hospital has been created to address some of the educational needs of the nursing and multi-professional team. The post holder is involved in a wide range of educational initiatives, from national bespoke study days and academic cancer care modules to ward based teaching. It is clear that there is a need for a role that combines clinical practice and academia, bridging the theory to practice gap and providing expert clinical knowledge to nurses caring for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Ellard: Honoraria (self): MolMed; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Kite Gilead. All other authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract